-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
What Is The Ownership Structure Like For Porton Pharma Solutions Ltd. (SZSE:300363)?
What Is The Ownership Structure Like For Porton Pharma Solutions Ltd. (SZSE:300363)?
Every investor in Porton Pharma Solutions Ltd. (SZSE:300363) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don't tell me what you think, tell me what you have in your portfolio.
Porton Pharma Solutions is a pretty big company. It has a market capitalization of CN¥37b. Normally institutions would own a significant portion of a company this size. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Porton Pharma Solutions.
Check out our latest analysis for Porton Pharma Solutions
SZSE:300363 Ownership Breakdown July 26th 2022What Does The Institutional Ownership Tell Us About Porton Pharma Solutions?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Porton Pharma Solutions. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Porton Pharma Solutions, (below). Of course, keep in mind that there are other factors to consider, too.
SZSE:300363 Earnings and Revenue Growth July 26th 2022Porton Pharma Solutions is not owned by hedge funds. Our data shows that Chongqing Liangjiang New Area Development & Investment Group Co., Ltd. is the largest shareholder with 15% of shares outstanding. Nianfeng Ju is the second largest shareholder owning 11% of common stock, and Rong Tao holds about 8.1% of the company stock. Rong Tao, who is the third-largest shareholder, also happens to hold the title of Vice Chairman.
We did some more digging and found that 6 of the top shareholders account for roughly 52% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Porton Pharma Solutions
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our most recent data indicates that insiders own a reasonable proportion of Porton Pharma Solutions Ltd.. Insiders own CN¥10.0b worth of shares in the CN¥37b company. That's quite meaningful. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 26% stake in Porton Pharma Solutions. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
Our data indicates that Private Companies hold 19%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Porton Pharma Solutions better, we need to consider many other factors. For example, we've discovered 1 warning sign for Porton Pharma Solutions that you should be aware of before investing here.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
波顿医药解决方案有限公司(深圳证券交易所股票代码:300363)的每一位投资者都应该知道最强大的股东群体。内部人士通常持有大量较年轻、规模较小的公司,而大公司往往有机构作为股东。我通常喜欢看到一定程度的内部人持股,即使只是一小部分。正如纳西姆·尼古拉斯·塔勒布所说,不要告诉我你的想法,告诉我你的投资组合中有什么。
波顿制药解决方案公司是一家相当大的公司。其市值为370亿元人民币。通常情况下,机构会持有如此规模的公司的很大一部分股份。我们对公司所有权的分析如下所示,机构拥有公司的股份。让我们仔细看看不同类型的股东能告诉我们关于Porton Pharma Solutions的什么。
查看我们对Porton Pharma Solutions的最新分析
深交所:300363股权明细2022年7月26日关于Porton Pharma Solutions,机构所有权告诉了我们什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
正如你所看到的,机构投资者在Porton Pharma Solutions拥有相当数量的股份。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时会做出糟糕的投资,就像每个人一样。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,有必要看看Porton Pharma Solutions过去的盈利轨迹(见下图)。当然,请记住,还有其他因素需要考虑。
深交所:2022年7月26日收益和收入增长300363Porton Pharma Solutions不为对冲基金所有。我们的数据显示,重庆两江新区开发投资集团有限公司是第一大股东,持有15%的流通股。念丰聚是第二大股东,持有11%的普通股,荣涛持有公司约8.1%的股份。作为第三大股东的荣涛也恰好持有副董事长的头衔。
我们做了更多的挖掘,发现大股东中有6个约占登记册的52%,这意味着除了大股东外,还有一些小股东,从而在一定程度上平衡了彼此的利益。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。有很多分析师在追踪这只股票,所以他们的预测可能也是值得的。
波顿制药解决方案的内部人所有权
公司内部人的定义可能是主观的,而且在不同的司法管辖区之间确实有所不同。我们的数据反映了个别内部人士,至少捕捉到了董事会成员。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
内部人持股是积极的,当它标志着领导层像公司的真正所有者一样思考时。然而,高内部人持股也可以给公司内部的一个小团体带来巨大的权力。在某些情况下,这可能是负面的。
我们的最新数据显示,内部人士持有波顿制药解决方案有限公司相当比例的股份。内部人士在370亿元的公司中持有价值10.0亿元的股份。这是很有意义的。大多数人会说,这表明与股东的关系很好,特别是在这样一家规模如此大的公司。你可以点击这里,看看这些内部人士是一直在买入还是卖出。
一般公有制
公众通常是个人投资者,他们持有Porton Pharma Solutions 26%的股份。虽然这群人不一定能发号施令,但它肯定能对公司的运营方式产生真正的影响。
私营公司所有权
我们的数据显示,私营公司持有该公司19%的股份。或许有必要对此进行更深入的研究。如果关联方,如内部人士,对这些私营公司中的一家有利害关系,则应在年报中披露。私营公司也可能对该公司拥有战略利益。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但为了更好地理解Porton Pharma Solutions,我们需要考虑许多其他因素。例如,我们发现波顿制药解决方案的1个警告标志在这里投资之前你应该意识到这一点。
如果你像我一样,你可能会想一想这家公司是会增长还是会萎缩。幸运的是,您可以查看这份显示分析师对其未来预测的免费报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧